Current state of biomarker development for clinical application in epithelial ovarian cancer (Q35100951)

6 August 2017

1 reference

title

Current state of biomarker development for clinical application in epithelial ovarian cancer (English)

1 reference

6 August 2017

0 references

1 reference

3

Robert C Bast

1 reference

6 August 2017

Richard G Moore

1

1 reference

PubMed ID

19879639

6 August 2017

Shannon MacLaughlan

series ordinal

2

1 reference

PubMed ID

19879639

6 August 2017

language of work or name

English

0 references

publication date

31 October 2009

1 reference

6 August 2017

1 reference

6 August 2017

116

1 reference

6 August 2017

2

1 reference

6 August 2017

240-245

1 reference

Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125.

6 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134885

p53 autoantibodies, cytokine levels and ovarian carcinogenesis

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134885

Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134885

Results from four rounds of ovarian cancer screening in a randomized trial

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134885

Development and preliminary evaluation of a multivariate index assay for ovarian cancer

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134885

The accuracy of risk scores in predicting ovarian malignancy: a systematic review

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134885

Urinary levels of Bcl-2 are elevated in ovarian cancer patients

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134885

A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134885

Identification of differentially expressed proteins in ovarian cancer using high-density protein microarrays

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134885

Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134885

Risk of malignancy index for referral of ovarian cancer cases to a tertiary center: does it identify the correct cases?

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134885

Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134885

New tumor markers: CA125 and beyond.

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134885

Potential markers that complement expression of CA125 in epithelial ovarian cancer

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134885

Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134885

Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134885

The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma.

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134885

ACOG Committee Opinion: number 280, December 2002. The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134885

Epithelial ovarian cancer: prevention, diagnosis, and treatment

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134885

p53 Antibodies in the sera of patients with various types of cancer: a review

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134885

Elevation of multiple serum markers in patients with stage I ovarian cancer.

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134885

Management of the adnexal mass

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134885

Reactivity of a monoclonal antibody with human ovarian carcinoma

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134885

Staging Laparotomy in Early Ovarian Cancer

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134885

A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134885

Misstaging of ovarian cancer.

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134885

The clinical correlates of serum CA125 in 169 patients with epithelial ovarian carcinoma

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134885

CA 125 assay used in conjunction with CA 15-3 and TAG-72 assays for discrimination between malignant and non-malignant diseases of the ovary

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134885

Pretreatment serum levels of CA-125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase in patients with ovarian carcinoma: influence of histological type, grade of differentiation, and clinical stage of disease

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134885

Validation of serum biomarkers for detection of early-stage ovarian cancer.

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134885

Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134885

Preoperative evaluation and triage of women with suspicious adnexal masses using risk of malignancy index

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134885

Protein expression levels of carcinoembryonic antigen (CEA) in Danish ovarian cancer patients: from the Danish 'MALOVA'ovarian cancer study.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134885

The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134885

Predictors of comprehensive surgical treatment in patients with ovarian cancer.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134885

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134885

Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134885

Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134885

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134885

Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134885

Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134885

Identifying novel autoantibody signatures in ovarian cancer using high-density protein microarrays

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134885

Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses

16 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134885

The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma

16 November 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.041

A population-based study of patterns of care for ovarian cancer: who is seen by a gynecologic oncologist and who is not?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.041

Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.041

Ovarian cancer: patterns of surgical care across the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.041

Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.041

A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.041

Diagnostic markers for early detection of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.041

Prospective multicenter study on CA 125 in postmenopausal pelvic masses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.041

Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses. Discrimination of benign from malignant disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.041

What is a normal CA125 level?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.041

Serum tumor marker immunoassays in gynecologic oncology: establishment of reference values

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.041

Elevated serum inhibin concentrations in postmenopausal women with ovarian tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.041

Total Inhibin Is a Potential Serum Marker for Epithelial Ovarian Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.041

Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.041

Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.09.041

National Institutes of Health Consensus Development Conference Statement. Ovarian cancer: screening, treatment, and follow-up

7 January 2021

1 reference

12 December 2020

The risk-of-malignancy index to evaluate potential ovarian cancers in local hospitals

1 reference

12 December 2020

Guidelines for referral to a gynecologic oncologist: rationale and benefits. The Society of Gynecologic Oncologists

1 reference

12 December 2020

Preoperative evaluation of serum CA 125 levels in patients with primary epithelial ovarian cancer

1 reference

12 December 2020

Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer

1 reference

12 December 2020

10.1016/J.YGYNO.2009.09.041

Identifiers

DOI

1 reference

6 August 2017

1 reference

6 August 2017

1 reference

PubMed ID

19879639